RT Journal Article
SR Electronic
A1 Hoyle, Brian
T1 Reductions in HbA1c and Weight in Type 2 Diabetics with the Empagliflozin Add-On Regimen
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 20
SP 15
OP 17
DO 10.1177/155989771420009
UL http://mdc.sagepub.com/content/14/20/15.abstract
AB Empagliflozin is a potent and selective inhibitor of sodium glucose cotransporter 2. This article discusses an extension study, the Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes study [EMPA-REG EXTEND MET; NCT01289990], assessed the long-term safety, tolerability, and efficacy of the empagliflozin add-on regimen.